our mission

TriSalus Life Sciences® seeks to extend and improve the lives of patients living with liver and pancreatic tumors.

Illustration of the two organs, two problems, two solutions approach that TriSalus is working on. Two organs: the liver and pancreas in an elderly, male patient. Addressing two problems: immunosuppression and tumor pressure which causes blood vessel collapse. Combining two solutions: immunotherapy via pressure enabled drug delivery.
Addressing two problems: immunosuppression and tumor pressure which causes blood vessel collapse.
Combining two solutions: immunotherapy via pressure enabled drug delivery.

We’re developing a transformative platform to address barriers to the treatment of liver and pancreatic tumors.

Two critical barriers, intratumoral pressure and an immunosuppressive environment, limit the delivery and efficacy of immunotherapies in tumors of the liver and pancreas.

We believe that comprehensively addressing these two barriers has the potential to improve the lives of patients with liver and pancreatic tumors. Our therapeutic platform is designed to be used in combination with, and enable, systemic immunotherapies like checkpoint inhibitors.

Our Science

Learn about how TriSalus aims to address two of the most significant barriers to treatment.

 

Video Thumbnail with text: Prologue
Play Video about Video Title Slide: Prologue
See Our Platform in Action

TriSalus takes an integrated approach tailored to the target organ and disease biology, with the goal to overcome two critical barriers: immunosuppression and delivery.

Watch to learn how our platform approach applies to the treatment of liver tumors.

Share video

Recent News

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

November 14, 2024

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

November 11, 2024

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

November 07, 2024

Our Pipeline

We’re studying the integration of the Pressure-Enabled Drug Delivery™ (PEDD™) method with therapies capable of reactivating immune cells to enable immunotherapies in the liver and pancreas. Our clinical research is focused on bringing this potentially transformative treatment platform to patients.

PIPELINE

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

CANCEL